MCRR Refugees Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : MCRR Refugees

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: out_of_the_loop who wrote (301)	7/20/1998 9:22:00 AM
From: Graham Marshman	Read Replies (1) of 582

OK, thanks. Personally, I was not looking for your endorsement of stock performance based on this input, just clarifying your medical opinion. You are right that the web site still reflects the telomere angle. Antisense delivery is a recent focus due largely to the test results and large business opportunity with existing antisense companies with patented molecules already. These guys will fight the good fight with the FDA. As for the stock, you are right that it could be some time before product revenues from the vector business arrive. Current question is with that preclinically proven and potential antisense business along with their other lines, is it worth more than the current $30M market cap. My answer's a clear yes, but everyone's welcome to make up their own mind. Good luck in the others and thanks again for the opinion. Graham

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next